Dr. Capell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University Of Washington Medical Ctr
1959 Ne Pacific St
Seattle, WA 98195Phone+1 206-525-2408- Is this information wrong?
Education & Training
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1968 - 1971
University of Rochester School of Medicine and DentistryClass of 1968
University of WashingtonFellowship, Endocrinology, Diabetes, and Metabolism
Certifications & Licensure
WA State Medical License 1971 - 2021
Publications & Presentations
PubMed
- 291 citationsPhase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functiona...Laurie L. Carr, David A. Mankoff, Bernardo H. L. Goulart, Keith D. Eaton, Peter T. Capell, Elizabeth M. Kell, Julie E. Bauman, Renato G. Martins> ;Clinical Cancer Research. 2010 Nov 1
- Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC).Carr L, Goulart B, Martins R, Keith E, Kell E, Wallace S, Capell P, Mankoff D> ;J. Clin. Oncol.. 2009-05-20
- Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC).Goulart B, Carr L, Martins RG, Eaton K, Kell E, Wallace S, Capell P, Mankoff D> ;J. Clin. Oncol.. 2008-05-20
- Join now to see all
Hospital Affiliations
UW Medicine/University of Washington Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
